Why neoadjuvant androgen deprivation prior to radical prostatectomy is unnecessary

Urologic Clinics of North America

Volumn 23, Issue 4, 1996, Pages 587-604

  Abbas, F ^a   Scardino, P T ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUTAMIDE; GONADORELIN;

CANCER ADJUVANT THERAPY; CANCER SURGERY; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVIEW; TREATMENT PLANNING;

EID: 0030479372     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0094-0143(05)70338-4     Document Type: Article

References (121)

1. D.A. Ackerman J.M. Barry R.A. Wicklund Analysis of risk factors associated with prostate cancer extension to the surgical margin and pelvic node metastasis at radical prostatectomy J Urol 150 1993 1845 1852
2. J. Adolfsson G. Steineck Whitmore W.F. Jr Recent results of management of palpable clinically localized prostate cancer Cancer 72 1993 310 322
3. E.A. Andros F. Daneshgari E.D. Crawford Neoadjuvant hormone therapy in stage C adenocarcinoma of the prostate Clin Invest Med 16 1993 510 515
4. O.A. Armas A.G. Aprikan J. Melamed Clinical and pathobiological effects of total androgen ablation on clinically localized prostatic carcinoma J Urol 149 1993 347A
5. O.A. Armas A.G. Aprikan J. Melamed Clinical and pathological results of neoadjuvant total androgen ablation therapy on clinically localized prostatic adenocarcinoma Am J Surg Pathol 18 1994 979 991
6. G. Aus S. Brandstedt M. Haggman Effects of 3 months' neoadjuvant hormonal treatment with a GnRH analogue (Triptorelin) prior to radical retropubic prostatectomy on prostate-specific antigen and tumor volume in prostate cancer Eur Urol 26 1994 22 28
7. M.A. Bagshaw R.S. Cox S.L. Hancock Control of prostate cancer with radiotherapy: The long-term results J Urol 152 1994 1781
8. J.B. Beck M.W. Kattan B.J. Miles A critique of the decision analysis for clinically localized prostate cancer J Urol 152 1994 1894 1899
9. R.J. Bosch K.H. Kurth F.H. Schroeder Surgical treatment of locally advanced (T3) prostatic carcinoma. Early results J Urol 138 1987 816
10. N. Bruchovsky P.S. Rennie A.J. Coldman Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma Cancer Res 50 1990 2275 2282
11. W.J. Catalona Surgical management of prostate cancer: Contemporary results with anatomical radical prostatectomy Cancer 75 1995 1903
12. W.J. Catalona S.W. Bigg Nerve-sparing radical prostatectomy: Evaluation of results after 250 patients J Urol 143 1990 538 546
13. W.J. Catalona D.S. Smith 5-Year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer J Urol 152 1994 1837 1842
14. M.L. Cher K. Shinohara S. Breslin High failure rate associated with long-term follow-up of neoadjuvant androgen deprivation followed by radical prostatectomy for stage C prostate cancer Br J Urol 75 1995 771 777
15. G.W. Chodak Treatment of early stage prostate cancer: Conservative management-delayed therapy V.T. DeVita S. Hellman Rosenberg S.A. Important Advances in Oncology 1994 JB Lippincott Philadelphia 241 244
16. G.W. Chodak R.A. Thisted G.A. Gerber Results of conservative management of clinically localized prostate cancer N Engl J Med 330 1994 242 248
17. R. Chute B.M. Fox Nonresectable carcinoma of the prostate rendered resectable by endocrine therapy J Urol 95 1966 577 579
18. D.W. Cohen A. Aprikan P. Russo Neoadjuvant total androgen ablation combined with radical prostatectomy for clinically localized carcinoma of the prostate J Urol 151 1994 435A
19. J.A.C. Colston H. Brendler Endocrine therapy in carcinoma of the prostate JAMA 134 1947 848 853
20. M.D. Cosgrove F.W. Cerge R. Terry The effects of treatment on the local lesion of carcinoma of the prostate J Urol 109 1973 861 865
21. R.L. Cox E.D. Crawford Estrogens in the treatment of prostate cancer J Urol 154 1995 1991
22. F. Daneshgari E.D. Crawford E. Andros Neoadjuvant hormonal therapy of patients with clinical stage C prostate cancer J Urol 149 1993 348 A
23. F.M.J. Debruyne W.P.J. Witjes C.C. Schulman A multicentric trial of combined neoadjuvant androgen blockade with zoladex and flutamide prior to radical prostatectomy in prostate cancer Eur Urol 26 suppl 1 1994 4
24. J.I. Epstein M. Carmichael A.W. Partin Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of followup J Urol 149 1993 1478 1485
25. J.I. Epstein G. Pizov P.C. Walsh Correlation of pathologic findings with progression after radical retropubic prostatectomy Cancer 71 1993 3582 3593
26. W.R. Fair A.G. Aprikian D. Cohen Use of neoadjuvant androgen deprivation therapy in clinically localized prostate cancer Clin Invest Med 16 1993 516 522
27. W.R. Fair A. Aprikian V. Reuter Neoadjuvant hormonal manipulation: A strategy for chemoprevention trials J Cell Biochem 118 suppl 16H 1992 118 121
28. W.R. Fair A. Aprikian P. Sogani The role of neoadjuvant hormonal manipulation in localized prostate cancer Cancer 71 1993 1031 1038
29. W.R. Fair W.D.W. Heston Is combined modality therapy appropriate for apparently localized carcinoma of the prostate Urol Clin North Am 18 1991 477 479
30. W.R. Fair Y. Wang D. Cohen Neoadjuvant androgen deprivation therapy (ADT) in patients with clinically localized prostate cancer-effects on (+) margins and postoperative PSA J Urol 153 1995 313A
31. J. Flamm M. Fischer W. Holtl Complete androgen deprivation prior to radical prostatectomy in patients with stage T3 cancer of the prostate Eur Urol 19 1991 192 195
32. C. Fleming J.H. Wasson P.C. Albertsen A decision analysis of alternative treatment strategies for clinically localized prostate cancer JAMA 269 1993 2650 2658
33. F.J. Fowler M.J. Barry G. Lu-Yao Effect of radical prostatectomy for prostate cancer on patient quality of life: Results from a medicare survey Urology 45 1995 1007
34. W.F. Gee H.L. Holtgrewe P.C. Albertsen Practice trends in the diagnosis and management of prostate cancer in the United States J Urol 154 1995 207 208
35. R.P. Gibbons R.J. Correa G.E. Brannen Total prostatectomy for clinically localized prostate cancer: Long-term results J Urol 141 1989 564 566
36. M.E. Gleave M. Boden N. Bruchovsky Predictors of time to androgen-independent progression in the LNCaP prostate tumor model J Urol 151 1994 458A
37. M.E. Gleave L. Goldenberg N. Bruchovsky Long-term neoadjuvant hormonal therapy prior to radical prostatectomy in localized prostate cancer J Urol 151 1994 831 A
38. M.E. Gleave S.L. Goldenberg E.C. Jones Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer J Urol 155 1995 213 219
39. M.E. Gleave J.T. Hsieh H.C. Wu Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors Cancer Res 52 1992 1598 1603
40. D.A. Gobet H. Knonagel D. Hauri Endocrine treatment prior to radical retropubic prostatectomy in patients with T3 prostate cancer: A retrospective study of 22 patients Urol Int 49 1992 141 145
41. S.L. Goldenberg L.H. Klotz M.A.S. Jewett Randomized, controlled study of neoadjuvant reversible androgen withdrawal therapy with cyproterone acetate in the surgical management of localized prostate cancer J Urol 153 1995 254A
42. R. Guiterrez New horizons in the surgical management of carcinoma of the prostate Am J Surg 78 1949 147 169
43. M. Haagman M. Hellstrom G. Aus Neoadjuvant GnRH-agonist treatment (Triptorelin and Cyproterone acetate for flare protection) and total prostatectomy Eur Urol 24 1993 456 460
44. G.E. Hanks A. Hanlon T. Schultheiss Early prostate cancer: The national results of radiation treatment from the patterns of care and radiation therapy oncology group studies with prospects for improvement with conformal radiation and adjuvant androgen deprivation J Urol 152 1994 1775
45. M. Hellstrom M. Haggman S. Brandstedt Histopathological changes in androgen-deprived localized prostatic cancer Eur Urol 24 1993 461 465
46. J.E. Johansson Expectant management of early stage prostate cancer: Swedish experience J Urol 152 1994 1753 1756
47. S.S. Johansson E. Ljunggren Prostatic carcinoma cured with hormonal treatment. A report of 2 cases Scand J Urol Nephrol 15 1981 331 332
48. E.C. Jones Resection margin status in radical retropubic prostatectomy specimens: Relationship to type of operation, tumor size, tumor grade and local tumor extension J Urol 144 1990 89 93
49. M.W. Kattan B.J. Miles J.R. Beck Re-examination of the decision analysis for clinically localized prostate cancer: Age and grade comparisons J Urol 153 1995 390A
50. M.W. Kattan B.J. Miles J.R. Beck Second order Monte Carlo simulation in the decision to treat clinically localized prostate cancer Med Decis Making 15 1995 429
51. T.J. Kennedy A.M. Sonneland M.M. Marlett Luteinizing hormone-releasing hormone downstaging of clinical stage C prostate cancer J Urol 147 1992 891 893
52. M.W. Kollermann P. Sprenk V. Muhlfait Downstaging of stage C prostatic carcinoma by inductive chemo-hormonal therapy? Eur Urol 24 1993 337 342
53. N. Kyprianou H. English J. Isaacs Programmed cell death during regression of PC-82 human prostatic cancer following androgen ablation Cancer Res 50 1990 3748 3753
54. F. Labrie A. Belanger A. Dupont Science behind total androgen blockade: From gene to combination therapy Clin Invest Med 16 1993 475 492
55. F. Labrie L. Cusan J.L. Gomez Downstaging by combination therapy with flutamide and an LHRH agonist before radical prostatectomy Cancer Surv 23 1995 149 156
56. F. Labrie L. Cusan J.L. Gomez Extensive personal experience: Combination of screening and preoperative endocrine therapy: The potential for an important decrease in prostate cancer mortality J Clin Endocrinol Metab 80 1995 2002 2013
57. F. Labrie A. Dupont L. Cusan Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: The first controlled and randomized trial Clin Invest Med 16 1993 499 509
58. F. Labrie A. Dupont J.L. Gomez Beneficial effect of combination therapy administered prior to radical prostatectomy J Urol 149 1993 348 A
59. F. Lee D.B. Siders J.E. Newby The role of transrectal ultrasound-guided staging biopsy and androgen ablation therapy prior to radical prostatectomy Clin Invest Med 16 1993 458 470
60. M.E. Leo D.L. Bilhartz E.J. Bergstrahl Prostate specific antigen in hormonally treated stage D2 prostate cancer: Is it always an accurate indicator of disease status? J Urol 145 1991 802
61. A.J. Lim A.H. Brandon J. Fiedler Quality of life: Radical prostatectomy versus radiotherapy for prostate cancer J Urol 154 1995 1420
62. M.T. Macfarlane A. Abi-Aad A. Stein Neoadjuvant hormonal deprivation in patients with locally advanced prostate cancer J Urol 147 1992 246 A
63. F.J. Mayer E.D. Crawford The role of endocrine therapy in the management of local and distant recurrence of prostate cancer following radical prostatectomy or radiation therapy Urol Clin North Am 21 1994 707 715
64. B.J. Miles M.W. Kattan Computer modeling of prostate cancer treatment: A paradigm for oncologic management? Surg Oncol Clin North Am 4 1995 361
65. G. Monfette A. Dupont F. Labrie Temporary combination therapy with flutamide and tryptex as adjuvant to radical prostatectomy for the treatment of early stage prostate cancer F. Labrie F. Lee Dupont A. Early Stage Prostate Cancer: Diagnosis and Choice of Therapy 1989 Elsevier Amsterdam 41 51
66. W.R. Morgan E.J. Bergstralh H. Zincke Long-term evaluation of radical prostatectomy as treatment for clinical stage C (T3) prostate cancer Urology 41 1993 113 120
67. W.R. Morgan H. Zincke L.M. Rainwater Prostate specific antigen values after radical retropubic prostatectomy for adenocarcinoma of the prostate: Impact of adjuvant treatment (hormonal and radiation) J Urol 145 1991 319 323
68. A.M. Mottrie C. Mappes M. Stockle Neoadjuvant hormonal treatment in clinical stage C prostate cancer J Urol 149 1993 347 A
69. W.M. Murphy M.S. Soloway G.H. Barrows Pathologic changes associated with androgen deprivation therapy for prostate cancer Cancer 68 1991 821 828
70. P. Narayan B.A. Lowe P.R. Carrol Neoadjuvant hormonal therapy and radical prostatectomy for clinical stage C carcinoma of the prostate Br J Urol 73 1994 544 548
71. J.E. Oesterling P.E. Andrews V.J. Suman Preoperative androgen deprivation therapy: Artificial lowering of serum prostate specific antigen without downstaging the tumor J Urol 149 1993 779 782
72. M. Ohori P.T. Scardino S.L. Lapin The mechanisms and prognostic significance of seminal vesicle involvement by prostate cancer Am J Surg Pathol 17 1993 1252 1261
73. M. Ohori T.M. Wheeler M.W. Kattan Prognostic significance of positive surgical margins in radical prostatectomy specimens J Urol 154 1995 1818 1824
74. F.P. O'Malley D.J. Grignon D.T. Shum Usefulness of immunoperoxidase staining with high-molecular weight cytokeratin in the differential diagnosis of small-acinar lesions of the prostate gland Virchows Arch 417 1990 191 196
75. A.L. Parlow W.W. Scott Hormone control therapy as a preparation for radical perineal prostatectomy in advanced carcinoma of the prostate N Y State J Med 49 1949 629 634
76. A.W. Partin H.B. Carter D.W. Chan Prostate-specific antigen in the staging of localized prostate cancer: Influence of tumor differentiation, tumor volume and benign hyperplasia J Urol 143 1990 747 752
77. A.W. Partin C.R. Pound J.Q. Clemens Serum PSA after anatomic radical prostatectomy: The Johns Hopkins experience after 10 years Urol Clin North Am 20 1993 713 725
78. D.F. Paulson Impact of radical prostatectomy in the management of clinically localized disease J Urol 152 1994 1826 1830
79. D.F. Paulson J.W. Moul P.J. Walther Radical prostatectomy for clinical stage T1-2N0M0 prostatic adenocarcinoma: Long-term results J Urol 144 1990 1180 1184
80. S. Pinault B. Tetu J. Gagnon Transrectal ultrasound evaluation of local prostate cancer in patients treated with LHRH agonist and in combination with flutamide Urology 39 1992 254 261
81. K. Pummer E.D. Crawford F. Daneshgari Hormonal pretreatment does not affect the final pathologic stage in locally advanced prostate cancer Urology 44 1994 38 42
82. L.M. Rainwater W.R. Morgan G.G. Klee Prostate-specific antigen testing in untreated and treated prostatic adenocarcinoma Mayo Clin Proc 65 1990 1118 1124
83. M.A. Rosen L. Goldstone S. Lapin Frequency and location of extracapsular extension and positive surgical margins in radical prostatectomy specimens J Urol 148 1992 331 337
84. A.M. Sassine C.C. Schulman Neoadjuvant androgen deprivation before radical prostatectomy Eur Urol 24 suppl 2 1993 46 50
85. N. Sato M.E. Gleave S.L. Goldenberg Intermittent androgen suppression delays time to androgen independent progression in the LNCaP prostate tumor model J Urol 153 suppl 1995 282A
86. P.T. Scardino J.R. Beck B.J. Miles Conservative management of prostate cancer. N Engl J Med 330:1831, 1994: editorial comment on Chodak GW, Thisted RA, Gerber GS, et al: Results of conservative management of clinically localized prostate cancer N Engl J Med 330 1994 242 248
87. F.H. Schroeder Van Den Ouden D. P.J.T. Davidson Radical prostatectomy in T3 carcinoma of the prostate—a prospective study of 100 consecutive cases J Urol 149 1993 348A
88. C.C. Schulman Neoadjuvant androgen blockade prior to prostatectomy: A retrospective study and critical review Prostate 5 1994 9 14
89. C.C. Schulman F.M.J. Debruyne P. Ekman Workshop summary: Hormonal suppression in the neoadjuvant setting and advanced disease Eur Urol 24 suppl 2 1993 61 63
90. C.C. Schulman A.M. Sassine Neoadjuvant androgen deprivation before radical prostatectomy Clin Invest Med 16 1993 523 531
91. W.W. Scott An evaluation of endocrine therapy plus radical perineal prostatectomy in the treatment of advanced carcinoma of the prostate J Urol 91 1964 97 102
92. W.W. Scott H.L. Boyd Combined hormone control therapy and radical prostatectomy in the treatment of selected cases of advanced carcinoma of the prostate: A retrospective study based upon 25 years of experience J Urol 101 1969 86 92
93. W.U. Shipley A.L. Zietman G.E. Hanks Treatment related sequelae following external beam radiation for prostate cancer: A review with an update in patients with stages T1 and T2 tumor J Urol 152 1994 1799
94. D.M. Smith W.M. Murphy Histologic changes in prostate carcinomas treated with Leuprolide (luteinizing hormone-releasing hormone effect): Distinction from poor tumor differentiation Cancer 73 1994 1472 1477
95. M.H. Solomon T.A. McHugh R.P. Dorr Hormone ablation therapy as neoadjuvant treatment to radical prostatectomy Clin Invest Med 16 1993 532 538
96. M.S. Soloway Role of induction androgen deprivation before radical prostatectomy Semin Urol 13 1995 142 147
97. M.S. Soloway T. Hachiya F. Civantos Androgen deprivation prior to radical prostatectomy for T2b and T3 prostate cancer Urology 43 suppl 2 1994 52 56
98. M.S. Soloway T. Hachiya H.E. Ruiz Significance of androgen deprivation prior to radical prostatectomy with special reference to prostate-specific antigen World J Urol 11 1993 221 226
99. M.S. Soloway R. Sharifi Z. Wajsman Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer J Urol 154 1995 424 428
100. S. Song M. Ohori M.W. Kattan Has there been a recent shift towards earlier stage cancer among patients treated with radical prostatectomy J Urol 153 1995 428A
101. T.A. Stamey F.S. Freiha J.E. McNeal Localized prostate cancer: Relationship of tumor volume to clinical significance for treatment of prostate cancer Cancer 71 1993 933 938
102. T.A. Stamey J.N. Kabalin J.E. McNeal Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients J Urol 141 1989 1076 1083
103. T.A. Stamey A.A. Villers J.E. McNeal Positive surgical margins at radical prostatectomy: Importance of apical dissection J Urol 143 1990 1166 1173
104. T.A. Stamey N. Yang A.R. Hay Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate N Engl J Med 317 1987 909 914
105. A.M.F. Stapleton P.T. Scardino Nerve-sparing radical retropubic prostatectomy R.J. Krane J. Fitzpatrick Siroky M.B. Operative Urology 1996 Churchill Livingstone London
106. A. Stein J.B. DeKernion R.B. Smith Prostate specific antigen levels after radical prostatectomy in patients with organ confined and locally extensive prostate cancer J Urol 147 1992 942 946
107. B. Tetu F. Labrie A. Dupont Histopathological results of combination therapy on normal prostate and prostatic adenocarcinoma F. Labrie F. Lee Dupont A. Early Stage Prostate Cancer: Diagnosis and Choice of Therapy 1989 Excerpta Medica Amsterdam 63 75
108. B. Tetu J.R. Srigley J. Boivin Effect of combination endocrine therapy (LHRH agonist and Flutamide) on normal prostate and prostatic adenocarcinoma: A histopathologic and immunohistochemical study Am J Surg Pathol 15 1991 111 120
109. J.G. Trapasso deKernion J.B. R.B. Smith Incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy J Urol 152 1994 1821 1825
110. U.W. Tunn A.J.W. Goldschmidt S. Steigerwald Efficacy of neoadjuvant antiandrogenic treatment prior to radical prostatectomy J Urol 147 1992 246A
111. B.S. Vallet Radical perineal prostatectomy subsequent to bilateral orchiectomy Del Med J 16 1944 18 20
112. Van de Voorde W.M. A.A. Elgamal Van Poppel H.P. Morphologic and immunohistochemical changes in prostate cancer after preoperative hormonal therapy Cancer 74 1994 3164 3175
113. Van Poppel H. D.D. Ridder A.A. Elgamal Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer: Interim results of a prospective randomized trial J Urol 154 1995 429 434
114. J.M. Vapnek P.R. Carroll Neoadjuvant hormonal downstaging of clinical stage C carcinoma of the prostate J Urol 147 1992 247A
115. A. Villers J.E. McNeal E.A. Redwine The role of perineural space invasion in the local spread of prostatic adenocarcinoma J Urol 142 1989 763 770
116. P.C. Walsh Radical retropubic prostatectomy with reduced morbidity: An anatomic approach NCI Monogr 7 1988 133 148
117. P.C. Walsh A.W. Partin Treatment of early stage prostate cancer: Radical prostatectomy V.T. DeVita S. Hellman Rosenberg S.A. Important Advances in Oncology 1994 JB Lippincott Philadelphia 211 223
118. P.C. Walsh A.W. Partin J.I. Epstein Cancer control and quality of life following anatomical radical retropubic prostatectomy: Results at 10 years J Urol 152 1994 1831 1836
119. J. Warner Whitmore W.F. Jr Expectant management of clinically localized prostate cancer J Urol 152 1994 1761 1765
120. G.K. Zagars Prostate specific antigen as an outcome variable for T1 and T2 prostate cancer treated by radiation therapy J Urol 152 1994 1786
121. H. Zincke J.E. Oesterling M.L. Blute Long term (15 years) results after radical prostatectomy for clinically localized (stage t2c or lower) prostate cancer J Urol 152 1994 1850 1857